Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.
Gilead Sciences is building up its autoimmune disease drug pipeline by turning to EVOQ Therapeutics, a startup with technology that takes a novel approach to restoring immune tolerance. For EVOQ, the Gilead deal is its second with a big pharma company.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
An AstraZeneca lupus drug has been awarded FDA approval for treating the most common form of the autoimmune disorder. The regulatory decision gives AstraZeneca a product that can compete head-to-head with GlaxoSmithKline’s lupus drug, Benlysta.
During a panel discussion at the Connected Health Conference in Boston, two physicians and a patient touched on how virtual reality is aiding a variety of healthcare consumers. Yet as one panelist noted, we shouldn't overpromise what it can do.
Aurinia Pharmaceuticals put cashflow issues behind it on Tuesday, announcing a public offering that it expects will generate $150.5 million in gross proceeds for its Phase 3 trial in lupus nephritis. But not everyone was happy with the news.
Aurinia Pharmaceuticals took an existing drug and made just one amino acid modification. Is it another meaningless iteration, or could this drug really deliver major gains in lupus nephritis?
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Aurinia was the subject of acquisition rumors in October. Two months later, it's flying solo with $25 million in new financing to power its Phase 3 trial for lupus nephritis.
Albuquerque, N.M.-based Exagen Diagnostics has raised $25 million in debt financing with a strategic investment from Capital Royalty Partners. The healthcare startup focuses on molecular testing innovations in rheumatology diagnostics, including rheumatoid arthritis and lupus, with its Avise line. Sales success attracted the investor. “The company has shown tremendous sales success with their lead product, […]
The approval of Human Genome Sciences/GlaxoSmithKline’s Benlysta last year ended a drought of new drug approvals for the autoimmune disease lupus that had lasted more than half a century. A lengthy pipeline of drugs is hoping to follow suit, including a preclinical biologic compound from a University of Washington spinoff that is hoping to progress […]
The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early stage clinical trials, but the questions remain whether it’s enough progress to attract interest from a potential pharmaceutical partner. Argos released positive phase 1 clinical trial results for AGS-009 at the 2012 European League Against Rheumatism Congress (EULAR) in Berlin, […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
LabCorp (NYSE:LH) is partnering with molecular diagnostics firm XDx to develop a new diagnostic for lupus flares. Burlington, North Carolina-based LabCorp will work with XDx to develop a biomarker and commercialize a test for the flares — extended periods of activity for the autoimmune disease. Lupus causes the body’s immune system to attack its own […]